Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management
Juwei Yang1,2, Longfei Li2, Yiran Hu1
1The Cardiac Arrhythmia Center State Key Laboratory of Cardiovascular Disease, National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|February 14, 2025
Summary
Electroactive platforms convert energy into electrical signals for biomedical applications, particularly in cardiovascular care for managing heart rhythm disorders. This review covers advancements, applications, and challenges in electroactive systems for arrhythmia management.
Area of Science:
- Biomedical Engineering
- Cardiovascular Technology
- Materials Science
Background:
- Electroactive platforms are crucial for energy conversion in biomedical applications.
- Cardiovascular care increasingly utilizes these platforms for managing heart functions and disorders.
- Regulating cardiac electrical activity is key for novel arrhythmia management.
Purpose of the Study:
- To review recent advancements in electroactive systems for biomedical applications.
- To categorize electroactive systems by energy source and mechanism.
- To discuss applications in arrhythmia management and clinical translation challenges.
Main Methods:
- Literature review of electroactive systems.
- Categorization based on energy sources (e.g., self-powered) and mechanisms (e.g., conductive).
- Analysis of applications in monitoring, intervention, pacing, and cardiac repair.
Main Results:
- Electroactive systems show significant potential in cardiovascular care.
- Categorization includes self-powered and conductive systems.
- Applications span arrhythmia monitoring, intervention, pacing, and repair.
Conclusions:
- Electroactive platforms offer innovative solutions for cardiac rhythm management.
- Further research is needed to address challenges for clinical translation.
- Future opportunities lie in refining these technologies for widespread use.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
889
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
889
01:28Mechanism of Cardiac Arrhythmias
879
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
879
01:26Heart Failure Drugs: Inotropic Agents
500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
703
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
703
01:19Electrophysiology of Normal Cardiac Rhythm
2.0K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.0K